Clinical trials
Advanced Hepatocellular Carcinoma (HCC) clinical trials
Below are recruiting advanced hepatocellular carcinoma (hcc) clinical trials, each written for real people, not researchers. We’re tracking 210 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06999694RecruitingPhase 2
Proton radiation with immunotherapy for liver cancer
This trial tests combining proton beam radiation with two immunotherapy drugs (tremelimumab and durvalumab) for people with intermediate or advanced liver cancer (HCC) that cannot be removed by surgery. The goal is to see if this combination can shrink tumors and improve outcomes.
Taoyuan City, TaiwanAges 18 years+ - NCT07012798RecruitingPhase 2
Sequential therapy for advanced liver cancer that may become removable
This trial tests a sequence of chemotherapy (FOLFOX), immunotherapy (durvalumab), targeted therapy (bevacizumab), and focused radiation to shrink liver tumors that are not removable now, with the goal of making them operable later.
Tianjin, Tianjin MunicipalityAges 18 years+ - NCT07018518RecruitingPhase 1
Pin and immunotherapy combo for advanced liver cancer
This trial tests a new treatment combining a drug called PIN with an immunotherapy (anti-PD1) for people with advanced liver cancer (HCC) that has stopped responding to standard treatments. The goal is to see if this combination can shrink tumors or control the disease.
Beijing, Biotherapeutic Department of Chinsese PLA Gereral HospitalAges 18–75 - NCT07042919RecruitingPhase 1/Phase 2
Zanzalintinib for advanced liver cancer after prior treatment
This trial tests a new drug called zanzalintinib for people with advanced liver cancer (HCC) that can't be treated with surgery. You may join if your cancer has gotten worse after at least one prior treatment, or you couldn't tolerate that treatment.
Chicago, IllinoisAges 18 years+ - NCT07047586RecruitingPhase 2
Lenvatinib plus Tislelizumab vs Lenvatinib alone for liver cancer
This trial tests whether combining two targeted drugs (lenvatinib and tislelizumab) works better than lenvatinib alone for people with advanced liver cancer whose disease worsened after prior treatment with an immunotherapy and a blood vessel growth blocker (bevacizumab).
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT07052253RecruitingPhase 2
Combination therapy for advanced liver cancer
This trial tests two experimental drugs (AK104 and AK112) combined with an oral tablet (TT-00420) for people with advanced hepatocellular carcinoma (a type of liver cancer) who have not had previous systemic treatment. The goal is to see if this combination can shrink tumors or slow cancer growth.
Wuhan, ChinaAges 18–75 - NCT07070076Recruiting
Y-90 therapy vs chemo infusion for liver cancer
This study compares two liver-directed treatments—radioactive Yttrium-90 beads (SIRT) and a type of chemo infusion directly into the liver (HAIC)—for people whose liver cancer is advanced enough to need treatment but might still be removable with surgery. The goal is to see which approach can shrink the tumor best before surgery.
Guangzhou, GuangdongAges 18–75 - NCT07075120RecruitingPhase 1
Immunotherapy and radiation for advanced liver cancer
This trial tests a combination of two immunotherapy drugs (ipilimumab and nivolumab) plus targeted radiation (SBRT) for people with liver cancer that is advanced but has not spread outside the liver. The goal is to see if this approach can shrink tumors and make them easier to remove with surgery.
Honolulu, HawaiiAges 18 years+ - NCT07100392RecruitingPhase 2
A new drug combo for advanced liver cancer after first treatment fails
This study tests a combination of three drugs—TUDCA (a bile acid supplement), camrelizumab (an immunotherapy), and regorafenib (a targeted therapy)—for people with advanced liver cancer that has continued to grow after earlier immunotherapy plus Avastin treatment. The goal is to see if this new mix can help stop the cancer from growing.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT07106827RecruitingPhase 1
Study of a new drug for advanced or resistant solid tumors
This trial tests a new drug, GV20-0251, for people with advanced solid tumors that have not responded to standard treatments. It aims to see if the drug is safe and helpful.
Chengdu, SichuanAges 18 years+ - NCT07157969RecruitingPhase 2
Immunotherapy and anti-VEGF with or without local therapy for liver cancer
This trial tests a combination of immunotherapy (checkpoint inhibitors) and anti-VEGF therapy (which blocks blood vessel growth to tumors) with or without local treatments (like chemoembolization) for advanced liver cancer. It aims to see if the combination works better than current treatments.
BeijingAges 18 years+ - NCT07166406RecruitingPhase 3
Immunotherapy with or without targeted radiation for advanced liver cancer
This trial tests whether adding a precise, targeted form of radiation (called SBRT) to standard immunotherapy (atezolizumab and bevacizumab) can help people with advanced liver cancer that has spread to the blood vessels or outside the liver. You may be asked to participate in one of two treatment groups to see which approach works better.
Berkeley, CaliforniaAges 18 years+ - NCT07174570RecruitingPhase 2
Celecoxib with immunotherapy for advanced liver cancer
This trial tests a combination of two immunotherapy drugs (durvalumab and tremelimumab) plus a pain reliever (celecoxib) for people with advanced liver cancer that cannot be removed by surgery. The goal is to see if this three-drug combination works better than standard treatments.
Atlanta, GeorgiaAges 18 years+ - NCT07176650RecruitingPhase 1
Testing a biosimilar ipilimumab for advanced liver cancer
This trial tests a new version of the immunotherapy drug ipilimumab (called HLX13) against the approved version (YERVOY) for people with advanced liver cancer that cannot be removed by surgery. The goal is to see if the new version works similarly and is as safe.
Glendale, CaliforniaAges 18–65 - NCT07192185RecruitingPhase 2
Chemo plus immunotherapy for advanced liver cancer after first treatment fails
This trial tests a new combination of chemotherapy (FOLFOX) plus atezolizumab and bevacizumab for people with advanced liver cancer that has grown after having atezolizumab and bevacizumab alone. The goal is to see if adding chemo helps stop the cancer from growing further.
Guangzhou, GuangdongAges 18–75 - NCT07197554RecruitingPhase 1
A study of an experimental drug for advanced solid tumors
This trial tests a new drug, ST-01156, designed to attack cancer cells by breaking down a protein called RBM39. It may be an option for people with advanced solid tumors that have not responded to other treatments.
Duarte, CaliforniaAges 16 years+ - NCT07246668RecruitingPhase 2
Carbon ion radiation with immunotherapy for advanced liver cancer
This trial tests a combination of carbon ion radiation therapy with two drugs, atezolizumab and bevacizumab, for people with advanced liver cancer that cannot be surgically removed. The goal is to see if this approach is safe and effective.
SeoulAges 20 years+ - NCT07285850RecruitingPhase 2/Phase 3
Sequential treatment for advanced liver cancer with fatty liver
This trial tests a combination of two medications, bevacizumab and atezolizumab, given one after the other to treat advanced liver cancer that cannot be surgically removed. It is specifically for people whose liver cancer is linked to a fatty liver condition (MASLD). The goal is to see if this approach helps shrink tumors or control the disease.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT07291076RecruitingPhase 1/Phase 2
Study of Pumitamig with Ipilimumab for first-line advanced liver cancer
This trial tests a new drug called pumitamig, either alone or with another drug (ipilimumab), for people with advanced liver cancer that hasn't been treated yet. The goal is to see if these drugs can help shrink or control the cancer.
Duarte, CaliforniaAges 18 years+ - NCT07293468RecruitingPhase 2/Phase 3
Comparing two treatments for advanced liver cancer
This trial tests two different ways to treat liver cancer that can't be removed with surgery. It compares stereotactic body radiation therapy (targeted high-dose radiation) with selective internal radiation therapy (tiny radioactive beads delivered through a blood vessel), both combined with immunotherapy (medicines that help your immune system fight cancer).
Hong KongAges 18–80 - NCT07310173RecruitingPhase 2
Study of AST-3424 for advanced liver cancer with high AKR1C3
This trial tests a new drug called AST-3424 in people with advanced liver cancer that has gotten worse after prior treatment. It is for those whose tumor cells have high levels of a protein called AKR1C3, which the drug targets.
Nanjing, JiangsuAges 18–75 - NCT07327034RecruitingPhase 2
ABSK-011 with standard care for advanced liver cancer
This trial tests a new drug, ABSK-011, combined with standard care, against a placebo with standard care for people with advanced liver cancer that has a specific marker called FGF19 overexpression. The goal is to see if ABSK-011 can help slow the disease.
Hefei, AnhuiAges 18 years+ - NCT07364357RecruitingPhase 1
Study of CREPT-618 for advanced liver cancer
This phase 1 trial tests a new drug called CREPT-618 for people with advanced liver cancer that hasn't responded to standard treatments. The drug is designed to target cancer cells with specific markers (CREPT and ASGPR), so only patients whose tumors have these markers can join.
BeijingAges 18–75 - NCT07405086RecruitingPhase 4
Morning vs. afternoon immunotherapy for advanced solid tumors
This trial compares giving immunotherapy in the morning versus the afternoon to see if timing affects how well it works. It is for people with certain types of advanced or metastatic solid tumors who have not had this treatment before.
Portland, OregonAges 18 years+
Hear when a new Advanced Hepatocellular Carcinoma (HCC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for advanced hepatocellular carcinoma (hcc)?
- Yes. Clin2 currently lists 210 recruiting advanced hepatocellular carcinoma (hcc) studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a advanced hepatocellular carcinoma (hcc) trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a advanced hepatocellular carcinoma (hcc) trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.